EcoDrugPlus

Arginine Vasopressin Receptor 2

Ensembl ID : ENSTNIG00000012407
Gene Symbol: AVPR2
3 Cross references
148 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSTNIG00000015090
Gene Symbol: AVPR2
3 Cross references
178 Possible Orthologues:

Aurora Kinase A

Ensembl ID : ENSTNIG00000007048
Gene Symbol: AURKA
2 Cross references
232 Possible Orthologues:

Aurora Kinase B

Ensembl ID : ENSTNIG00000015730
Gene Symbol: AURKB
2 Cross references
205 Possible Orthologues:

Beta-Secretase 1

Ensembl ID : ENSTNIG00000014351
Gene Symbol: BACE1
2 Cross references
218 Possible Orthologues:

Bradykinin Receptor B1

Ensembl ID : ENSTNIG00000000275
Gene Symbol: BDKRB1
2 Cross references
147 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSTNIG00000001532
Gene Symbol: BDKRB2
3 Cross references
285 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSTNIG00000007580
Gene Symbol: CACNA1C
2 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSTNIG00000014681
Gene Symbol: CACNA1DA
2 Cross references
170 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSTNIG00000014174
Gene Symbol: CACNA1FB
2 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, B

Ensembl ID : ENSTNIG00000015082
Gene Symbol: CACNA1SB
2 Cross references
199 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSTNIG00000011310
Gene Symbol: CACNA1AB
2 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).